These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 8562906

  • 1. Targeted therapy of carcinomas using BR96 sFv-PE40, a single-chain immunotoxin that binds to the Le(y) antigen.
    Siegall CB.
    Semin Cancer Biol; 1995 Oct; 6(5):289-95. PubMed ID: 8562906
    [Abstract] [Full Text] [Related]

  • 2. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts.
    Friedman PN, Chace DF, Trail PA, Siegall CB.
    J Immunol; 1993 Apr 01; 150(7):3054-61. PubMed ID: 8454873
    [Abstract] [Full Text] [Related]

  • 3. BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells.
    Friedman PN, McAndrew SJ, Gawlak SL, Chace D, Trail PA, Brown JP, Siegall CB.
    Cancer Res; 1993 Jan 15; 53(2):334-9. PubMed ID: 8417827
    [Abstract] [Full Text] [Related]

  • 4. In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats.
    Siegall CB, Chace D, Mixan B, Garrigues U, Wan H, Paul L, Wolff E, Hellström I, Hellström KE.
    J Immunol; 1994 Mar 01; 152(5):2377-84. PubMed ID: 8133048
    [Abstract] [Full Text] [Related]

  • 5. BR96 sFv-PE40 immunotoxin: nonclinical safety assessment.
    Haggerty HG, Warner WA, Comereski CR, Peden WM, Mezza LE, Damle BD, Siegall CB, Davidson TJ.
    Toxicol Pathol; 1999 Mar 01; 27(1):87-94. PubMed ID: 10367679
    [Abstract] [Full Text] [Related]

  • 6. Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma.
    Henry CJ, Buss MS, Hellström I, Hellström KE, Brewer WG, Bryan JN, Siegall CB.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):751-5. PubMed ID: 15701865
    [Abstract] [Full Text] [Related]

  • 7. Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy.
    Siegall CB, Haggerty HG, Warner GL, Chace D, Mixan B, Linsley PS, Davidson T.
    J Immunol; 1997 Nov 15; 159(10):5168-73. PubMed ID: 9366448
    [Abstract] [Full Text] [Related]

  • 8. Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen.
    Francisco JA, Gilliland LK, Stebbins MR, Norris NA, Ledbetter JA, Siegall CB.
    Cancer Res; 1995 Jul 15; 55(14):3099-104. PubMed ID: 7541711
    [Abstract] [Full Text] [Related]

  • 9. Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs.
    Siegall CB, Liggitt D, Chace D, Mixan B, Sugai J, Davidson T, Steinitz M.
    Clin Cancer Res; 1997 Mar 15; 3(3):339-45. PubMed ID: 9815690
    [Abstract] [Full Text] [Related]

  • 10. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors.
    Posey JA, Khazaeli MB, Bookman MA, Nowrouzi A, Grizzle WE, Thornton J, Carey DE, Lorenz JM, Sing AP, Siegall CB, LoBuglio AF, Saleh MN.
    Clin Cancer Res; 2002 Oct 15; 8(10):3092-9. PubMed ID: 12374676
    [Abstract] [Full Text] [Related]

  • 11. Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice.
    Reiter Y, Wright AF, Tonge DW, Pastan I.
    Int J Cancer; 1996 Jul 03; 67(1):113-23. PubMed ID: 8690511
    [Abstract] [Full Text] [Related]

  • 12. Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation.
    Kuan CT, Pastan I.
    Proc Natl Acad Sci U S A; 1996 Feb 06; 93(3):974-8. PubMed ID: 8577771
    [Abstract] [Full Text] [Related]

  • 13. Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model.
    Kreitman RJ, Chang CN, Hudson DV, Queen C, Bailon P, Pastan I.
    Int J Cancer; 1994 Jun 15; 57(6):856-64. PubMed ID: 8206679
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells.
    Akamatsu Y, Murphy JC, Nolan KF, Thomas P, Kreitman RJ, Leung SO, Junghans RP.
    Clin Cancer Res; 1998 Nov 15; 4(11):2825-32. PubMed ID: 9829749
    [Abstract] [Full Text] [Related]

  • 16. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity.
    Siegall CB, Liggitt D, Chace D, Tepper MA, Fell HP.
    Proc Natl Acad Sci U S A; 1994 Sep 27; 91(20):9514-8. PubMed ID: 7937798
    [Abstract] [Full Text] [Related]

  • 17. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma.
    Onda M, Wang QC, Guo HF, Cheung NK, Pastan I.
    Cancer Res; 2004 Feb 15; 64(4):1419-24. PubMed ID: 14973056
    [Abstract] [Full Text] [Related]

  • 18. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice.
    Benhar I, Pastan I.
    Clin Cancer Res; 1995 Sep 15; 1(9):1023-9. PubMed ID: 9816075
    [Abstract] [Full Text] [Related]

  • 19. Cytotoxicity of chimeric (human-murine) monoclonal antibody BR96 IgG, F(ab')2, and Fab' conjugated to Pseudomonas exotoxin.
    Siegall CB, Gawlak SL, Chin JJ, Zoeckler ME, Kadow KF, Brown JP, Braslawsky GR.
    Bioconjug Chem; 1992 Sep 15; 3(4):302-7. PubMed ID: 1390985
    [Abstract] [Full Text] [Related]

  • 20. Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys.
    Pai LH, Batra JK, FitzGerald DJ, Willingham MC, Pastan I.
    Cancer Res; 1992 Jun 01; 52(11):3189-93. PubMed ID: 1591729
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.